AdAlta Ltd. ( (AU:1AD) ) has issued an announcement.
AdAlta Limited has secured its first external investment for its ‘East to West’ cellular immunotherapy strategy through a seed financing agreement with SYNthesis BioVentures. This investment will accelerate the development and licensing of three cellular immunotherapy assets, positioning AdAlta to bring Asian innovations to Western markets. The agreement signifies a vote of confidence in AdAlta’s strategy and is expected to enhance the company’s market positioning and operational capabilities.
More about AdAlta Ltd.
AdAlta Limited is a biotechnology company focused on developing innovative cellular immunotherapy solutions, particularly targeting solid tumors. The company aims to bridge Eastern innovations in cellular immunotherapy, particularly from Asia and China, to Western markets, leveraging Australia’s clinical and manufacturing capabilities.
YTD Price Performance: -50.0%
Average Trading Volume: 416,130
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$5.15M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.